Regeneron's monoclonal antibody treatment lowers the risk of death from COVID-19 by 20% in hospitalized patients with severe illness who haven't produced a natural immune response, according to preliminary results of the Randomised Evaluation of COVID-19 Therapy (RECOVERY) phase 3 trial.
The results were published on the medRxiv preprint server yesterday.Earlier studies had found that Regeneron's combination of casirivimab and imdevimab (REGEN-COV) reduces viral load, leads to a shorter duration of symptoms, and cuts the risk of hospitalization and death in nonhospitalized coronavirus patients, and a small study suggested a clinical benefit in hospitalized COVID-19 patients with no antibody response to infection.